Commercially Available Immunoglobulins Contain Virus Neutralizing Antibodies Against All Major Genotypes of Polyomavirus BK

Neutralizing antibodies (NAbs) form the basis of immunotherapeutic strategies against many important human viral infections. Accordingly, we studied the prevalence, titer, genotype‐specificity, and mechanism of action of anti‐polyomavirus BK (BKV) NAbs in commercially available human immune globulin (IG) preparations designed for intravenous (IV) use. Pseudovirions (PsV) of genotypes Ia, Ib2, Ic, II, III, and IV were generated by co‐transfecting a reporter plasmid encoding luciferase and expression plasmids containing synthetic codon‐modified VP1, VP2, and VP3 capsid protein genes into 293TT cells. NAbs were measured using luminometry. All IG preparations neutralized all BKV genotypes, with mean EC50 titers as high as 254 899 for genotype Ia and 6,666 for genotype IV. Neutralizing titers against genotypes II and III were higher than expected, adding to growing evidence that infections with these genotypes are more common than currently appreciated. Batch to batch variation in different lots of IG was within the limits of experimental error. Antibody mediated virus neutralizing was dose dependent, modestly enhanced by complement, genotype‐specific, and achieved without effect on viral aggregation, capsid morphology, elution, or host cell release. IG contains potent NAbs capable of neutralizing all major BKV genotypes. Clinical trials based on sound pharmacokinetic principles are needed to explore prophylactic and therapeutic applications of these anti‐viral effects, until effective small molecule inhibitors of BKV replication can be developed.

[1]  S. Linnenweber-Held,et al.  Donor origin of BKV replication after kidney transplantation. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  S. Saxena,et al.  Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals , 2014, Archives of Disease in Childhood.

[3]  K. Whaley,et al.  Antibody-based concepts for multipurpose prevention technologies. , 2013, Antiviral research.

[4]  E. Bouza,et al.  BK polyomavirus genotyping at inter‐ and intra‐patient level in Spain , 2013, Journal of medical virology.

[5]  C. Buck,et al.  BK Polyomavirus Genotypes Represent Distinct Serotypes with Distinct Entry Tropism , 2013, Journal of Virology.

[6]  B. Kessler,et al.  Detection of BK virus in urine from renal transplant subjects by mass spectrometry , 2012, Clinical Proteomics.

[7]  D. Brennan,et al.  Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients , 2012, PLoS pathogens.

[8]  J. Kant,et al.  VP‐1 quasispecies in human infection with polyomavirus BK , 2012, Journal of medical virology.

[9]  M. Humbert,et al.  An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV , 2011, PloS one.

[10]  J. Sellarésa,et al.  Understanding the Causes of Kidney Transplant Failure : The Dominant Role of Antibody-Mediated Rejection and Nonadherence , 2011 .

[11]  U. Maggiore,et al.  Increased viral load after intravenous immunoglobulin therapy for BK virus‐associated nephropathy , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[12]  P. Randhawa,et al.  Polyomavirus BK Neutralizing Activity in Human Immunoglobulin Preparations , 2010, Transplantation.

[13]  J. Levitsky,et al.  Viral Hepatitis in Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  D. Burton,et al.  Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L , 2009, Journal of Virology.

[15]  Christian Meisel,et al.  Sustained BK Viruria as an Early Marker for the Development of BKV-Associated Nephropathy: Analysis of 4128 Urine and Serum Samples , 2009, Transplantation.

[16]  A. Azzi,et al.  Antibody Responses to Recombinant Polyomavirus BK Large T and VP1 Proteins in Young Kidney Transplant Patients , 2009, Journal of Clinical Microbiology.

[17]  D. Burton,et al.  Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers , 2009, PLoS pathogens.

[18]  K. Abbott,et al.  An OPTN Analysis of National Registry Data on Treatment of BK Virus Allograft Nephropathy in the United States , 2009, Transplantation.

[19]  Philip R. Johnson,et al.  Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys , 2009, Nature Medicine.

[20]  F. Rehman,et al.  Intravenous immunoglobulin as rescue therapy for BK virus nephropathy , 2009, Pediatric transplantation.

[21]  M. Koukoulaki,et al.  Prospective monitoring of BK virus replication in renal transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[22]  J. Kant,et al.  Biologic diversity of polyomavirus BK genomic sequences: Implications for molecular diagnostic laboratories , 2008, Journal of medical virology.

[23]  D. Brennan,et al.  Longitudinal Analysis of Levels of Immunoglobulins against BK Virus Capsid Proteins in Kidney Transplant Recipients , 2008, Clinical and Vaccine Immunology.

[24]  B. Mayer,et al.  CMV‐hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta‐analysis , 2007, Clinical transplantation.

[25]  V. Dharnidharka,et al.  BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[26]  S. Brunet,et al.  Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. , 2006, The Journal of infectious diseases.

[27]  T. Larson,et al.  Kidney Transplant Function and Histological Clearance of Virus Following Diagnosis of Polyomavirus‐Associated Nephropathy (PVAN) , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  F. Rehman,et al.  Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. , 2006, Transplantation.

[29]  R. Orentas,et al.  BK Virus‐Specific Antibodies and BKV DNA in Renal Transplant Recipients with BKV Nephritis , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  G. Davis,et al.  A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[31]  P. Randhawa,et al.  Effect of Leflunomide and Cidofovir on Replication of BK Virus in an In Vitro Culture System , 2005, Transplantation.

[32]  M. Berger.  Subcutaneous immunoglobulin replacement in primary immunodeficiencies. , 2004, Clinical immunology.

[33]  S. Finkelstein,et al.  Correlates of Quantitative Measurement of BK Polyomavirus (BKV) DNA with Clinical Course of BKV Infection in Renal Transplant Patients , 2004, Journal of Clinical Microbiology.